Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

Pancreatic Cancer Clinical Trial

Official title:

A Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03883919
• Other study ID #: 201905201
• Status: Completed
• Phase: Phase 1
• Start date: July 11, 2019
• Est. completion date: July 2, 2022

Study information

• Verified date: October 2022
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Given the efficacy of nanoliposomal irinotecan as a second-line regimen in pancreatic ductal adenocarcinoma (PDAC), together with the favorable toxicity profile of paricalcitol and its interplay with irinotecan metabolism, the investigators propose a second-line pilot study in advanced PDAC that will enroll patients who have progressed on a gemcitabine-based regimen.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: July 2, 2022
• Est. primary completion date: March 23, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed pancreatic adenocarcinoma.

• Must have progressed on or become intolerant to gemcitabine-containing therapy in the advanced setting (not resectable). This is intended to be a second-line trial.

• Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 10 mm with CT scan, as = 20 mm by chest x-ray, or = 10 mm with calipers by clinical exam.

• At least 18 years of age.

• Life expectancy > 3 months.

• ECOG performance status = 1

• Normal bone marrow and organ function as defined below:

• Absolute neutrophil count = 1,500/mcL

• Platelets = 100,000/mcL

• Hemoglobin = 9 g/dL

• Total bilirubin = 1.5 x ULN

• Serum albumin > 3g/dL

• AST(SGOT)/ALT(SGPT) = 2.5 x IULN unless there are liver metastases, in which case AST and ALT = 5.0 x IULN

• Creatinine = 1.5 x IULN OR GFR > 50 mL/min

• Corrected calcium < 10.3 mg/dL

• Phosphorus = 4.5 mg/dL

• Patients will require a 2-week washout period from previous gemcitabine-based systemic therapy, a 2-week washout period from previous radiation therapy, and a 4-week washout period from major surgery prior to the first planned dose of study treatment.

• Prior clinically significant treatment-related toxicity must recover to grade 1 or less prior to the first planned dose of study treatment.

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• More than one prior systemic treatment in the advanced setting. Disease recurrence within 6 months of adjuvant therapy is considered one line of systemic treatment.

• Patients with active renal, ureteral, or bladder stones on the screening imaging.

• Current use of or anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatment.

• A history of other malignancy within 2 years previous, with the exception of those basal cell or squamous cell carcinoma of the skin which were treated with local resection only, or carcinoma in situ of the cervix.

• Currently receiving any other investigational agents.

• Patients who received FOLFIRINOX or FOLFIRI in the neoadjuvant or adjuvant setting who experienced disease recurrence within 6 months will be excluded (patients who received 5-FU or capecitabine as a radiosensitizer are permitted to enroll.)

• Patients with known active/ progressive brain metastases or leptomeningeal involvement will be excluded due to their poor prognosis. Patients with treated/stable brain metastases, defined as patients who have received prior therapy for their brain metastases and whose CNS disease is radiographically stable at study entry, are eligible.

• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to paricalcitol, liposomal irinotecan, 5-FU, LV, or other agents used in the study.

• Clinically significant ascites that requires therapeutic paracentesis or significant pleural effusion that requires therapeutic thoracentesis.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.

• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of study entry.

• Known HIV-positivity not on anti-retroviral therapy, or with CD4+ T cell count < 200/ul (patients with known HIV currently on anti-retroviral therapy with CD4+ T cell count > 200/ul will be included).

Related Conditions & MeSH terms

• Cancer of the Pancreas
• Pancreas Cancer
• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• 5-FU
-Standard of care drug
• Leucovorin
-Standard of care drug
• Liposomal Irinotecan
-Standard of care drug
• Paricalcitol
-Investigational drug

Procedure:
• Serum and plasma blood samples
-baseline, day 1 of each cycle beginning with cycle 2
• Tumor biopsy
5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1 After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible.

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	Ipsen

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tolerability between two different dose levels of paricalcitol added to the combo regimen of liposomal irinotecan plus 5-FU / LV as measured by the occurrence of grade 3 and 4 toxicities	-Toxicity will be graded using CTCAE version 5.0	Through 30 days after completion of paricalcitol treatment (estimated to be 28 weeks)
Secondary	Overall response rate (ORR)	The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and disappearance of all non-target lesions and normalization of tumor marker level.; Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.	Through completion of treatment (estimated to be 20 weeks)
Secondary	Progression-free survival (PFS)	PFS: PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.; Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).	Through completion of follow-up (estimated to be 72 weeks)
Secondary	Overall survival (OS)	-Overall survival (OS) is defined as the date from treatment to death or last follow-up.	Through completion of follow-up (estimated to be 72 weeks)
Secondary	CA19-9 biochemical response rate	-The biochemical response (BR) is defined as more than 50% of decrease from baseline CA 19-9.	Through beginning of cycle 10 (estimated to be 18 weeks)
Secondary	Duration of overall response	- The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).	Through completion of treatment (estimated to be 20 weeks)
Secondary	Duration of complete response	The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and disappearance of all non-target lesions and normalization of tumor marker level.	Through completion of treatment (estimated to be 20 weeks)
Secondary	Duration of stable disease	Duration of stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements.; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.	Through completion of treatment (estimated to be 20 weeks)

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine